Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD)

Area of Science:

• Pulmonology
• Clinical Pharmacology
• Epidemiology

Background:

• Traditional COPD pharmacotherapy trials often use spirometric criteria not suitable for all ages.
• This study re-evaluates combination therapy (salmeterol/fluticasone) in moderate-to-severe COPD using age-appropriate Global Lung Function Initiative (GLI) criteria.

Purpose of the Study:

• To assess the clinical effectiveness of salmeterol/fluticasone combination therapy in moderate-to-severe COPD.
• To utilize updated, age-appropriate spirometric criteria for patient stratification.

Main Methods:

• Analysis of data from the Towards a Revolution in COPD Health (TORCH) trial.
• Inclusion of 5688 participants with GLI-based moderate-to-severe COPD.
• Primary outcome: all-cause mortality; secondary outcomes: COPD mortality, cardiovascular mortality, and pneumonia.

Main Results:

• Combination therapy showed a non-significant reduction in all-cause mortality (adjHR 0.78, p=0.012).
• Non-significant reductions were observed for COPD and cardiovascular mortality.
• A statistically significant increase in pneumonia risk was found (adjHR 1.80, p<0.001).

Conclusions:

• Combination therapy in GLI-defined moderate-to-severe COPD increases pneumonia risk significantly.
• Mortality benefits were not statistically significant but may be clinically relevant.
• Age-appropriate spirometry is crucial for accurate COPD trial interpretation.